← Back to patent-cliff list
[18F]PSMA-11
Tier C — Watch / trade[18F]PSMA-11
Ghent University Hospital
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：PSMA
Indications (approved)：Thyroid cancer, Prostate cancer
Regional status
US
-
EU
Phase II
2018-06-15
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of [18F]PSMA-11?
Approved indications include: Thyroid cancer, Prostate cancer.
When does the [18F]PSMA-11 patent expire?
No public expiry year is available for [18F]PSMA-11 yet; this page updates once verified.
How do I get a quote for [18F]PSMA-11 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08